Co-Authors
This is a "connection" page, showing publications co-authored by BOGDAN A CZERNIAK and JIANJUN GAO.
Connection Strength
1.495
-
The origin of bladder cancer from mucosal field effects. iScience. 2022 Jul 15; 25(7):104551.
Score: 0.211
-
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.
Score: 0.208
-
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
Score: 0.203
-
Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020 06 16; 10(1):9743.
Score: 0.184
-
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
Score: 0.183
-
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
Score: 0.170
-
METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. Nat Commun. 2024 Aug 25; 15(1):7312.
Score: 0.061
-
Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 06; 148:1-6.
Score: 0.060
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
Score: 0.058
-
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
Score: 0.053
-
Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
Score: 0.053
-
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
Score: 0.050